What is FBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FBIO?

P/E (TTM) is 0.64 and 52-week range is $2.00 to $4.53 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FBIO?

The company profile lists revenue (TTM) near $72M, net income (TTM) near $117M, EPS (TTM) near $2.91 when available from the market-data feed. Figures are informational and may lag live markets.

Does FBIO show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.02, yield near 0.70% when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Fortress Biotech Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bay Harbor Islands, Florida, US, 33.2M shares outstanding, ISIN US34960Q3074 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Fortress Biotech Inc

$FBIO

Health Care · Biotechnology

IR Run Scenarios

$2.13

+2.15%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 78 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Employees

Website

www.fortressbiotech.com/

IPO

2011-11-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)